Overview

Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn the effectiveness of Sutent® (sunitinib malate, SU011248) in the treatment of patients with non-clear cell renal cell cancer. The safety of sunitinib malate will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Pfizer
Treatments:
Sunitinib